Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

L. Bazzola, C. Foroni, D. Andreis, V. Zanoni, M. R. Cappelletti, G. Allevi, S. Aguggini, C. Strina, M. Milani, S. Venturini, F. Ferrozzi, R. Giardini, R. Bertoni, H. Turley, K. Gatter, P. G. Petronini, S. B. Fox, A. L. Harris, M. Martinotti, A. BerrutiA. Bottini, A. R. Reynolds, D. Generali

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). Methods: Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In these patients we examined the pharmacokinetics of sorafenib and cyclophosphamide, toxicity of the regimen, the clinical response to therapy and changes in the levels of biologically relevant biomarkers. Results: Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with L+C. The mean plasma concentrations of C were consistently lower following administration of LCS, compared with administration of L+C only. The most common drug-related grade 3/4 adverse events were skin rash (69.3%), hand-foot skin reaction (69.3%) and diarrhoea (46.1%). According to RECIST Criteria, a clinical complete response was observed in 6 of 13 patients. A significant reduction in tumour size, evaluated with MRI, was also observed between baseline and 14 days of treatment in all 13 patients (P=0.005). A significant reduction in SUV uptake, measured by 18FDG-PET/CT, was observed in all patients between baseline and 30 days of treatment (P=0.015) and between baseline and definitive surgery (P=0.0002). Using modified CT Criteria, a response was demonstrated in 8 out of 10 evaluable patients at 30 days and in 11 out of 13 evaluable patients at the definitive surgery. A significant reduction in Ki67 expression was observed in all patients at day 14 compared with baseline (P

Original languageEnglish
Pages (from-to)52-60
Number of pages9
JournalBritish Journal of Cancer
Volume112
Issue number1
DOIs
Publication statusPublished - Jan 6 2015

Fingerprint

letrozole
Cyclophosphamide
Breast Neoplasms
Metronomic Administration
sorafenib
Fluorodeoxyglucose F18

Keywords

  • breast cancer
  • endocrine resistance
  • letrozole
  • neoadjuvant
  • primary hormone therapy
  • sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. / Bazzola, L.; Foroni, C.; Andreis, D.; Zanoni, V.; Cappelletti, M. R.; Allevi, G.; Aguggini, S.; Strina, C.; Milani, M.; Venturini, S.; Ferrozzi, F.; Giardini, R.; Bertoni, R.; Turley, H.; Gatter, K.; Petronini, P. G.; Fox, S. B.; Harris, A. L.; Martinotti, M.; Berruti, A.; Bottini, A.; Reynolds, A. R.; Generali, D.

In: British Journal of Cancer, Vol. 112, No. 1, 06.01.2015, p. 52-60.

Research output: Contribution to journalArticle

Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, Cappelletti, MR, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, PG, Fox, SB, Harris, AL, Martinotti, M, Berruti, A, Bottini, A, Reynolds, AR & Generali, D 2015, 'Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer', British Journal of Cancer, vol. 112, no. 1, pp. 52-60. https://doi.org/10.1038/bjc.2014.563
Bazzola, L. ; Foroni, C. ; Andreis, D. ; Zanoni, V. ; Cappelletti, M. R. ; Allevi, G. ; Aguggini, S. ; Strina, C. ; Milani, M. ; Venturini, S. ; Ferrozzi, F. ; Giardini, R. ; Bertoni, R. ; Turley, H. ; Gatter, K. ; Petronini, P. G. ; Fox, S. B. ; Harris, A. L. ; Martinotti, M. ; Berruti, A. ; Bottini, A. ; Reynolds, A. R. ; Generali, D. / Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. In: British Journal of Cancer. 2015 ; Vol. 112, No. 1. pp. 52-60.
@article{8301507f021d43ad92d675cf466614d9,
title = "Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer",
abstract = "Purpose: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). Methods: Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In these patients we examined the pharmacokinetics of sorafenib and cyclophosphamide, toxicity of the regimen, the clinical response to therapy and changes in the levels of biologically relevant biomarkers. Results: Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with L+C. The mean plasma concentrations of C were consistently lower following administration of LCS, compared with administration of L+C only. The most common drug-related grade 3/4 adverse events were skin rash (69.3{\%}), hand-foot skin reaction (69.3{\%}) and diarrhoea (46.1{\%}). According to RECIST Criteria, a clinical complete response was observed in 6 of 13 patients. A significant reduction in tumour size, evaluated with MRI, was also observed between baseline and 14 days of treatment in all 13 patients (P=0.005). A significant reduction in SUV uptake, measured by 18FDG-PET/CT, was observed in all patients between baseline and 30 days of treatment (P=0.015) and between baseline and definitive surgery (P=0.0002). Using modified CT Criteria, a response was demonstrated in 8 out of 10 evaluable patients at 30 days and in 11 out of 13 evaluable patients at the definitive surgery. A significant reduction in Ki67 expression was observed in all patients at day 14 compared with baseline (P",
keywords = "breast cancer, endocrine resistance, letrozole, neoadjuvant, primary hormone therapy, sorafenib",
author = "L. Bazzola and C. Foroni and D. Andreis and V. Zanoni and Cappelletti, {M. R.} and G. Allevi and S. Aguggini and C. Strina and M. Milani and S. Venturini and F. Ferrozzi and R. Giardini and R. Bertoni and H. Turley and K. Gatter and Petronini, {P. G.} and Fox, {S. B.} and Harris, {A. L.} and M. Martinotti and A. Berruti and A. Bottini and Reynolds, {A. R.} and D. Generali",
year = "2015",
month = "1",
day = "6",
doi = "10.1038/bjc.2014.563",
language = "English",
volume = "112",
pages = "52--60",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

AU - Bazzola, L.

AU - Foroni, C.

AU - Andreis, D.

AU - Zanoni, V.

AU - Cappelletti, M. R.

AU - Allevi, G.

AU - Aguggini, S.

AU - Strina, C.

AU - Milani, M.

AU - Venturini, S.

AU - Ferrozzi, F.

AU - Giardini, R.

AU - Bertoni, R.

AU - Turley, H.

AU - Gatter, K.

AU - Petronini, P. G.

AU - Fox, S. B.

AU - Harris, A. L.

AU - Martinotti, M.

AU - Berruti, A.

AU - Bottini, A.

AU - Reynolds, A. R.

AU - Generali, D.

PY - 2015/1/6

Y1 - 2015/1/6

N2 - Purpose: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). Methods: Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In these patients we examined the pharmacokinetics of sorafenib and cyclophosphamide, toxicity of the regimen, the clinical response to therapy and changes in the levels of biologically relevant biomarkers. Results: Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with L+C. The mean plasma concentrations of C were consistently lower following administration of LCS, compared with administration of L+C only. The most common drug-related grade 3/4 adverse events were skin rash (69.3%), hand-foot skin reaction (69.3%) and diarrhoea (46.1%). According to RECIST Criteria, a clinical complete response was observed in 6 of 13 patients. A significant reduction in tumour size, evaluated with MRI, was also observed between baseline and 14 days of treatment in all 13 patients (P=0.005). A significant reduction in SUV uptake, measured by 18FDG-PET/CT, was observed in all patients between baseline and 30 days of treatment (P=0.015) and between baseline and definitive surgery (P=0.0002). Using modified CT Criteria, a response was demonstrated in 8 out of 10 evaluable patients at 30 days and in 11 out of 13 evaluable patients at the definitive surgery. A significant reduction in Ki67 expression was observed in all patients at day 14 compared with baseline (P

AB - Purpose: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). Methods: Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In these patients we examined the pharmacokinetics of sorafenib and cyclophosphamide, toxicity of the regimen, the clinical response to therapy and changes in the levels of biologically relevant biomarkers. Results: Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with L+C. The mean plasma concentrations of C were consistently lower following administration of LCS, compared with administration of L+C only. The most common drug-related grade 3/4 adverse events were skin rash (69.3%), hand-foot skin reaction (69.3%) and diarrhoea (46.1%). According to RECIST Criteria, a clinical complete response was observed in 6 of 13 patients. A significant reduction in tumour size, evaluated with MRI, was also observed between baseline and 14 days of treatment in all 13 patients (P=0.005). A significant reduction in SUV uptake, measured by 18FDG-PET/CT, was observed in all patients between baseline and 30 days of treatment (P=0.015) and between baseline and definitive surgery (P=0.0002). Using modified CT Criteria, a response was demonstrated in 8 out of 10 evaluable patients at 30 days and in 11 out of 13 evaluable patients at the definitive surgery. A significant reduction in Ki67 expression was observed in all patients at day 14 compared with baseline (P

KW - breast cancer

KW - endocrine resistance

KW - letrozole

KW - neoadjuvant

KW - primary hormone therapy

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84920642492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920642492&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.563

DO - 10.1038/bjc.2014.563

M3 - Article

C2 - 25461806

AN - SCOPUS:84920642492

VL - 112

SP - 52

EP - 60

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -